ARTICLE SUMMARY:
In its search for novel treatment modalities beyond traditional biopharmaceutical, Glaxo SmithKline is focusing on bioelectronics, taking a deep dive into device technology.
Ask any medtech executive or investor to name the most promising opportunities in medical devices and odds are he or she will, sooner or later, point to neuromodulation.
